Related Experiment Video
Updated: Aug 25, 2026
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Engineered Exosomes as Next-generation Nanotherapeutics for Glioma: Crossing the Blood-brain Barrier Toward Precision
Shatrudhan Prajapati1,2, Shikha Yadav1
1Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India.
Background:
Glioma is one of the most aggressive and treatment-resistant malignancies of the central nervous system, characterized by rapid progression and poor prognosis. Conventional treatment approaches, including surgery, radiotherapy, and chemotherapy, often fail to achieve long-term remission due to the restrictive nature of the blood-brain barrier and the inherent heterogeneity of tumor cells.
Methods:
This review summarizes and critically analyzes current preclinical and clinical evidence on exosome biology, including their biogenesis, molecular cargo, and therapeutic engineering strategies. It further highlights recent advances in exosome-based delivery of chemotherapeutic agents, microRNAs, and gene-editing systems for glioma management.
Results:
Tumor- and stem cell-derived exosomes have demonstrated the ability to cross biological barriers while carrying functional biomolecules and modulating the tumor microenvironment. Their inherent stability, low immunogenicity, and capacity for surface modification make them promising nanocarriers for therapeutic applications. Engineered exosomes loaded with anti- tumor microRNAs, small interfering RNAs, or chemotherapeutic nanoparticles have shown promising results in enhancing drug sensitivity and reducing tumor proliferation in experimental glioma models.
Discussion:
The findings support the therapeutic potential of exosome-based platforms while also highlighting major challenges, including inconsistencies in isolation protocols, limited cargo- loading capacity, targeting specificity, and in vivo stability. Although exosomes have demonstrated the ability to overcome biological barriers and therapeutic resistance, standardized manufacturing protocols and robust clinical validation remain essential for successful clinical translation.
Conclusion:
Exosome-based systems represent a promising approach for the diagnosis and treatment of glioma. Their dual role as biomarkers and therapeutic drug carriers offers significant potential for personalized medicine through non-invasive disease monitoring and targeted therapeutic strategies. However, further optimization of large-scale production, purification methods, and clinical translation is necessary before exosome-based therapeutics can be integrated into standard glioma treatment protocols.
Insights
Exosomes show promise for treating aggressive brain tumors like glioma by overcoming drug resistance and the blood-brain barrier. Further research is needed to standardize exosome production and clinical application for effective glioma therapy.
Area of Science:
- Neuro-oncology
- Nanomedicine
- Biotechnology
Background:
- Glioma is a highly aggressive and treatment-resistant central nervous system malignancy with poor prognosis.
- Conventional treatments face limitations due to the blood-brain barrier and tumor cell heterogeneity.
Purpose of the Study:
- To review preclinical and clinical evidence on exosome biology and therapeutic engineering for glioma.
- To highlight advances in exosome-based delivery systems for glioma management.
Main Methods:
- Critical analysis of current literature on exosome biogenesis, cargo, and engineering.
- Review of exosome-based delivery of chemotherapeutics, microRNAs, and gene-editing systems.
Main Results:
- Exosomes can cross biological barriers and modulate the tumor microenvironment.
- Engineered exosomes show potential in enhancing drug sensitivity and reducing glioma proliferation.
- Exosomes offer stability, low immunogenicity, and surface modification capabilities for nanocarrier applications.
Conclusions:
- Exosome-based platforms hold therapeutic potential for glioma, overcoming resistance and biological barriers.
- Challenges include standardization of isolation, cargo loading, targeting specificity, and in vivo stability.
- Further optimization and clinical validation are crucial for integrating exosome therapeutics into standard glioma treatment.
